Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
From Jan 2020: how each company's value moved, whatever its size.
US$ billions, as reported in each year's annual results.
Revenue of the fiscal year. US dollars at each year's exchange rate.
| Measure | AstraZeneca PLC✕ AZN · #76 in the world | Pfizer Inc.✕ PFE · #126 in the world |
|---|---|---|
| Profile | ||
| Country | 🇬🇧 UK | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceutical | Pharmaceutical |
| Founded | 1999 | 1849 |
| Size | ||
| Market cap | $242.6 B | |
The largest companies, each against its nearest peers in value from the same industry.
| Fiscal year | AstraZeneca PLC | Pfizer Inc. |
|---|---|---|
| 2025 | $58.7 BSEC | $62.6 BSEC |
| 2024 | $54.1 BSEC | $63.6 BSEC |
| 2023 | $45.8 BSEC | $59.6 BSEC |
| 2022 | $44.4 BSEC | $101.2 BSEC |
| 2021 | $37.4 BSEC | $81.3 BSEC |
| 2020 | $26.6 BSEC | $41.7 BSEC |
| 2019 | $24.4 BSEC | $40.9 BSEC |
| 2018 | $22.1 BSEC | $40.8 BSEC |
| 2017 | $22.5 BSEC | $52.5 BSEC |
| 2016 | $23.0 BSEC | $52.8 BSEC |
| 2015 | $24.7 BSEC | $48.9 BSEC |
| 2014 | — | $49.6 BSEC |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports; Ed. = the company's report (editors); WD = Wikidata, citing the annual report; Cap = value.today market caps. Hover a figure for its period.
| $170.7 B |
| Revenue | $58.7 B | $62.6 B |
|---|
| Net income | $10.2 B▲ best | $7.8 B |
|---|
| Employees | 89,900 | 75,000 |
|---|
| Valuation | ||
|---|---|---|
| P/E ratio | 23.7× | 42.3× |
| Price to sales | 4.1× | 2.7× |
| Price to book | 5.0× | 2.0× |
| Free cash flow yield | 4.8% | 5.3%▲ best |
| Profitability | ||
|---|---|---|
| Gross margin | 81.9%▲ best | 74.3% |
| Operating margin | 23.4% | — |
| Net margin | 17.4%▲ best | 12.4% |
| Return on equity | 22.9%▲ best | 8.9% |
| Return on invested capital | 17.5% | — |
| Growth | ||
|---|---|---|
| Revenue growth | 8.6%▲ best | -1.6% |
| Revenue growth, 3 years a year | 9.8%▲ best | -14.8% |
| Earnings per share growth | 45.3%▲ best | -3.5% |
| Financial strength | ||
|---|---|---|
| Debt to equity | 0.5×▲ best | 0.7× |
| Interest cover | 8.1× | — |
| Cash | ||
|---|---|---|
| Free cash flow margin | 20.0%▲ best | 14.5% |
| Shareholder returns | ||
|---|---|---|
| Dividend yield | 2.0% | — |
| Shareholder yield | 2.3% | — |
| Strength scores | ||
|---|---|---|
| Piotroski F-score | 8 of 9▲ best | 5 of 9 |
| Altman Z-score zone | safe | — |
|---|
| Data as of | Market cap Aug 2026; ratios FY2025 | Market cap Oct 2026; ratios FY2025 |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.